ABD - İngilizce - NLM (National Library of Medicine)

bryant ranch prepack - guanfacine hydrochloride (unii: pml56a160o) (guanfacine - unii:30omy4g3mk) - guanfacine extended-release tablets are indicated for the treatment of attention deficit hyperactivity disorder (adhd) as monotherapy and as adjunctive therapy to stimulant medications [see clinical studies (14)] . guanfacine extended-release tablets are contraindicated in patients with a history of a hypersensitivity reaction to guanfacine extended-release tablets or its inactive ingredients, or other products containing guanfacine. rash and pruritus have been reported. pregnancy exposure registry   there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to adhd medications, including guanfacine extended-release tablets, during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for adhd medications at 1-866-961-2388.   risk summary available data with guanfacine over decades of use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes

ABD - İngilizce - NLM (National Library of Medicine)

bryant ranch prepack - guanfacine hydrochloride (unii: pml56a160o) (guanfacine - unii:30omy4g3mk) - guanfacine extended-release tablets are indicated for the treatment of attention deficit hyperactivity disorder (adhd) as monotherapy and as adjunctive therapy to stimulant medications [see clinical studies (14)] . guanfacine extended-release tablets are contraindicated in patients with a history of a hypersensitivity reaction to guanfacine extended-release tablets or its inactive ingredients, or other products containing guanfacine. rash and pruritus have been reported. pregnancy exposure registry   there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to adhd medications, including guanfacine extended-release tablets, during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for adhd medications at 1-866-961-2388.   risk summary available data with guanfacine over decades of use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes

Kanada - İngilizce - Health Canada

jamp pharma corporation - guanfacine (guanfacine hydrochloride) - tablet (extended-release) - 1mg - guanfacine (guanfacine hydrochloride) 1mg

Kanada - İngilizce - Health Canada

jamp pharma corporation - guanfacine (guanfacine hydrochloride) - tablet (extended-release) - 2mg - guanfacine (guanfacine hydrochloride) 2mg

Kanada - İngilizce - Health Canada

jamp pharma corporation - guanfacine (guanfacine hydrochloride) - tablet (extended-release) - 3mg - guanfacine (guanfacine hydrochloride) 3mg

Kanada - İngilizce - Health Canada

jamp pharma corporation - guanfacine (guanfacine hydrochloride) - tablet (extended-release) - 4mg - guanfacine (guanfacine hydrochloride) 4mg

ABD - İngilizce - NLM (National Library of Medicine)

par pharmaceutical inc. - guanfacine (unii: 30omy4g3mk) (guanfacine - unii:30omy4g3mk) - guanfacine 1 mg

ABD - İngilizce - NLM (National Library of Medicine)

avera mckennan hospital - guanfacine (unii: 30omy4g3mk) (guanfacine - unii:30omy4g3mk) - guanfacine 2 mg

ABD - İngilizce - NLM (National Library of Medicine)

cardinal health - esmolol hydrochloride (unii: v05260lc8d) (esmolol - unii:mdy902uxsr) - esmolol hydrochloride 10 mg in 1 ml - esmolol hydrochloride is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. esmolol hydrochloride is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. esmolol hydrochloride is intended for short-term use. esmolol hydrochloride is indicated for the short-term treatment of tachycardia and/or hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated. use of esmolol hydrochloride to prevent such events is not recommended. esmolol hydrochloride is contraindicated in patients with: pregnancy category c. esmolol hydrochloride has been shown to produce increa

Birleşik Krallık - İngilizce - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - guanfacine hydrochloride - oral tablet - 1mg